Assembly Biosciences, Inc. is a clinical-stage biopharmaceutical company that develops novel, oral small molecule therapies for severe viral infections. The company's pipeline features long-acting helicase-primase inhibitors, such as ABI-5366 and ABI-1179, which are in clinical development for recurrent genital herpes. Additionally, Assembly Biosciences is advancing candidates like ABI-4334, a next-generation capsid assembly modulator for chronic HBV, and ABI-6250, an orally bioavailable entry inhibitor for HDV. The company operates primarily in the United States and leverages a strategic collaboration with Gilead Sciences to advance its virology research and development programs.
